Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 13 10 2020
accepted: 22 10 2020
pubmed: 11 11 2020
medline: 3 3 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

Immune thrombocytopenia (ITP) is now well-known to reduce patients' health-related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I-WISh (ITP World Impact Survey) was an exploratory, cross-sectional survey designed to establish the multifaceted impact of ITP, and its treatments, on patients' lives. It focused on perceptions of 1507 patients and 472 physicians from 13 countries regarding diagnostic pathway, frequency and severity of signs and symptoms, and treatment use. Twenty-two percent of patients experienced delayed diagnosis (caused by several factors), 73% of whom felt anxious as a result. Patients rated fatigue among the most frequent, severe symptom associated with ITP at diagnosis (58% most frequent; 73% most severe), although physicians assigned it lower priority (30%). Fatigue was one of the few symptoms persisting at survey completion (50% and 65%, respectively) and was the top symptom patients wanted resolved (46%). Participating physicians were experienced at treating ITP, thereby recognizing the need to limit corticosteroid use to newly-diagnosed or first-relapse patients and espoused increased use of thrombopoietin receptor agonists and anti-CD20 after relapse in patients with persistent/chronic disease. Patient and physicians were largely aligned on diagnosis, symptoms, and treatment use. I-WISh demonstrated that patients and physicians largely align on overall ITP symptom burden, with certain differences, for example, fatigue. Understanding the emotional and clinical toll of ITP on the patient will facilitate shared decision-management, setting and establishment of treatment goals and disease stage-appropriate treatment selection.

Identifiants

pubmed: 33170956
doi: 10.1002/ajh.26045
pmc: PMC7898610
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-198

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2020 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Lancet. 2011 Jan 29;377(9763):393-402
pubmed: 20739054
Lancet. 2009 Feb 21;373(9664):641-8
pubmed: 19231632
J Thromb Haemost. 2015 Mar;13(3):457-64
pubmed: 25495497
J Thromb Haemost. 2010 Jun;8(6):1372-82
pubmed: 20230419
Eur J Haematol. 2009 Sep;83(3):175-82
pubmed: 19374704
Blood. 2008 Aug 15;112(4):999-1004
pubmed: 18463354
Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520
pubmed: 23714309
Blood. 2013 Jan 17;121(3):537-45
pubmed: 23169778
Am J Hematol. 2016 Oct;91(10):995-1001
pubmed: 27351715
Am J Hematol. 2015 Mar;90(3):E40-3
pubmed: 25400215
N Engl J Med. 2007 Nov 29;357(22):2237-47
pubmed: 18046028
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
Eur J Haematol. 2017 Apr;98(4):371-377
pubmed: 27981682
Br J Haematol. 2020 Oct;191(1):98-106
pubmed: 32501532
Br J Haematol. 2014 Jun;165(6):865-9
pubmed: 24725224
Blood Adv. 2019 Dec 10;3(23):3829-3866
pubmed: 31794604
Intern Med. 2016;55(17):2379-85
pubmed: 27580537
Br J Haematol. 2004 Apr;125(2):232-9
pubmed: 15059147
Br J Haematol. 2016 Jan;172(2):262-73
pubmed: 26537623
Am J Hematol. 2021 Feb 1;96(2):199-207
pubmed: 33107998
Blood. 2017 Dec 7;130(23):2527-2536
pubmed: 29042367
Br J Haematol. 2015 Jul;170(2):141-9
pubmed: 25823426
Am J Hematol. 2021 Feb 1;96(2):188-198
pubmed: 33170956
Ann Hematol. 2002 Aug;81(8):436-40
pubmed: 12224000
Blood. 2010 Jan 14;115(2):168-86
pubmed: 19846889
Br J Haematol. 2014 Oct;167(2):243-51
pubmed: 25041261
Am J Hematol. 2018 Jul;93(7):921-930
pubmed: 29696684
Blood. 2009 Mar 12;113(11):2386-93
pubmed: 19005182
N Engl J Med. 2010 Nov 11;363(20):1889-99
pubmed: 21067381
Br J Haematol. 2017 Apr;177(1):39-54
pubmed: 28295192
Transfusion. 2013 Nov;53(11):2807-12
pubmed: 23451917
Haematologica. 2019 Jun;104(6):1124-1135
pubmed: 31126963
J Thromb Haemost. 2012 Oct;10(10):1988-98
pubmed: 22863415
Blood Adv. 2017 Nov 28;1(25):2414-2420
pubmed: 29296891
Semin Hematol. 2013 Jan;50 Suppl 1:S83-8
pubmed: 23664524
Blood. 2012 Jun 21;119(25):5989-95
pubmed: 22566601
Lancet. 2008 Feb 2;371(9610):395-403
pubmed: 18242413
Blood. 2012 Aug 2;120(5):960-9
pubmed: 22740443
Br J Haematol. 2013 May;161(3):411-23
pubmed: 23432528
Lancet. 2015 Apr 25;385(9978):1653-61
pubmed: 25662413

Auteurs

Nichola Cooper (N)

Department of Haematology, Hammersmith Hospital, Imperial College London, London, UK.

Alexandra Kruse (A)

Platelet Disorder Support Association, Cleveland, Ohio, USA.

Caroline Kruse (C)

Platelet Disorder Support Association, Cleveland, Ohio, USA.

Shirley Watson (S)

Patient Representative for the UK ITP Forum, Bolnhurst, UK.

Mervyn Morgan (M)

ITP Support Association, Bolnhurst, UK.

Drew Provan (D)

Academic Haematology Unit, Blizard Institute, Barts and The School of Medicine and Dentistry, London, UK.

Waleed Ghanima (W)

Department of Medicine, Østfold Hospital Trust, Kalnes, Norway.
Department of Hematology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Donald M Arnold (DM)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

Yoshiaki Tomiyama (Y)

Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.

Cristina Santoro (C)

Hematology, University Hospital Policlinico Umberto I, Rome, Italy.

Marc Michel (M)

Department of Internal Medicine, National Referral Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.

Serge Laborde (S)

O'Cyto, Saint-Loubes, France.

Barbara Lovrencic (B)

Italian Association of Immune Thrombocytopenic Purpura, Caprino Veronese, Italy.

Ming Hou (M)

Department of Hematology, Shandong University, Jinan, China.

Tom Bailey (T)

Bespoke Team, Adelphi Real World, Macclesfield, UK.

Gavin Taylor-Stokes (G)

Bespoke Team, Adelphi Real World, Macclesfield, UK.

Jens Haenig (J)

Novartis Pharma AG, Basel, Switzerland.

James B Bussel (JB)

Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH